Bibliografía del artículo
1. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies.FEMS Microbiol Rev 31:52-63, 2007.
2. Claus H, Maiden MC, Wilson DJ, McCarthy ND, Jolley KA, Urwin R et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191:1263-1271, 2005.
3. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 344:1378-88, 2001.
4. Purcell B, Samuelsson S, Hahne SJM, Ehrhard I, Heuberger S, Camaroni I y col. Effectiveness of antibiotics in preventing meningococcal disease after a case: Systematic review. Br J Med 328:1339-43, 2004.
5. Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. The Cochrane Database of Systematic Reviews Issue 1. Art. No.: CD004785.pub2. 2005. DOI: 10.1002/14651858.CD004785.pub2.
6. Schwartz B, Al-Tobaiqi A, Al-Ruwais A, Fontaine RE, A'Ashi J, Hightower AW, et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis. Lancet 1:1239-42, 1988.
7. John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 18:188-93, 1994.
8. Deviatkina NP, Demina AA, Orlova EV, Timina VP, Petrova IS. Evaluation of the sanative action of rifampicin on the meningococcal carrier state. Antibiotiki 23:794-7, 1978.
9. Blakebrough IS, Gilles HM. The effect of rifampicin on meningococcal carriage in family contacts in northern Nigeria. J Infect 2:137-43, 1980.
10. Deal WB, Sanders E. Efficacy of rifampin in treatment of meningococcal carriers. N Engl J Med 281:641-5, 1969.
11. Guttler RB, Counts GW, Avent CK, Beaty HN. Effect of rifampin and minocycline on meningococcal carrier rates. J Infect Dis 124:199-205, 1971.
12. Kaiser AB, Hennekens CH, Saslaw MS, Hayes PS, Bennett JV. Seroepidemiology and chemoprophylaxis disease due to sulfonamide-resistant Neisseria meningitidis in a civillian population. J Infect Dis 130:217-24, 1974.
13. Munford RS, Sussuarana de Vasconcelos ZJ, Phillips CJ, Gelli DS, Gorman GW, Risi JB, et al. Eradication of carriage of Neisseria meningitidis in families: a study in Brazil. J Infect Dis 129:644-9, 1974.
14. Simmons G, Jones N, Calder L. Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria meningitidis. J Antimicrob Chemother 45:909-11, 2000.
15. Block C, Vázquez JA. Antibiotic Resistance in the chemoprophylaxis of meningococcal disease. In: Handbook of meningococcal disease. Infection biology, vaccination, clinical management. Frosch M, Maiden MCJ (eds.) pp. 53-59. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2006.
16. Simmons G, Jones N, Calder L. Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria meningitidis. J Antimicrob Chemother 45:909-11, 2000.
17. Lepe JA, Salcedo C, Alcalá B, Vázquez JA. Evolution of Neisseria meningitidis sensitivity to various antimicrobial drugs over the course of chemoprophylaxis during an epidemic outbreak. Enferm Infecc Microbiol Clin 24:608-12, 2006.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute Wayne, Pennsylvania, USA, 2007.
19. Carter PE, Abadi FJ, Yakubu DE, Pennington TH. Molecular characterization of rifampin-resistant Neisseria meningitidis. Antimicrob Agents Chemother 38:1256-61, 1994.
20. Nolte O, Muller M, Reitz S, Ledig S, Ehrhard I, Sonntag HG. Description of new mutations in the rpoB gene in rifampin-resistant Neisseria meningitidis selected in vitro in a stepwise manner. J Med Microbiol 52:1077-81, 2003.
21. Stefanelli P, Fazio C, La Rosa G, Marianelli C, Muscillo M, Mastrantonio P. Rifampin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains. J Antimicrob Chemother 47:219-22, 2001.
22. Stefanelli P, Neri A, Carattoli A, Mastrantonio P. Detection of resistance to rifampicin and decreased susceptibility to penicillin in Neisseria meningitidis by real-time multiplex polymerase chain reaction assay. Diagn Microbiol Infect Dis 58:241-4, 2007.
23. Carter PE, Abadi FJ, Yakubu DE, Pennington TH. Molecular characterization of rifampin-resistant Neisseria meningitidis. Antimicrob Agents Chemother 38:1256-61, 1994.
24. Abadi FJ, Carter PE, Cash P, Pennington TH. Rifampin resistance in Neisseria meningitidis due to alterations in membrane permeability. Antimicrob Agents Chemother 40:646-51, 1996.
25. Vazquez JA. The resistance of Neisseria meningitidis to the antimicrobial agents: an issue still in evolution. Rev Med Microbiol 12:39-45, 2001.
26. Taha MK, Zarantonelli ML, Ruckly C, Giorgini D, Alonso JM. Rifampin-resistant Neisseria meningitidis. Emerg Infect Dis 12:859-60, 2006.
27. Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant meningococcal disease. Emerg Infec Dis 11:977-9, 2005.
28. Bordessoule A, Hoppé A, Ringuier B, Giniès JL. Failure of chemoprophylaxis due to resistance of Neisseria meningitidis to rifampicin. Arch Pediatr 14:99-100, 2007.
29. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Weekly Rep 54:1-21, 2005.
30. Tzanakaki G, Blackwell CC, Kremastinou J, Kallergi C, Kouppari G, Weir DM. Antibiotic sensitivities of Neisseria meningitidis isolates from patients and carriers in Greece. Epidemiol Infect 108:449-55, 1992.
31. Alcala B, Salcedo C, de la Fuente L, Arreaza L, Uría MJ, Abad R et al. Neisseria meningitidis showing decreased susceptibility to ciprofloxacin: first report in Spain. J Antimicrob Chemother 53:409, 2004.
32. Corso A, Faccone D, Miranda M, Rodriguez M, Regueira M, Carranza C et al. Emergence of Neisseria meningitidis with decreased susceptibility to ciprofloxacin in Argentina. J Antimicrob Chemother 55;596-7, 2005.
33. Singhal S, Purnapatre KP, Kalia V, Dube S, Nair D, Deb M et al. Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. EID 13:1614-6, 2007.
34. Centers for Disease Control and Prevention (CDC). Emergence of fluoroquinolone-resistant Neisseria meningitidis --Minnesota and North Dakota, 2007-2008. MMWR Morb Mortal Wkly Rep 57:173-5, 2008.
35. Shultz TR, White PA, Tapsall JW. In vitro assessment of the further potential for development of fluoroquinolone resistance in Neisseria meningitidis. Antimicrob Agents Chemother 49:1753-60, 2005.
36. Orus P, Viñas M. Mechanisms other than penicillin-binding protein-2 alterations may contribute to moderate penicillin resistance in Neisseria meningitidis. Intern J Antimicrob Agents 18:113-9, 2001.
37. Engelen F, Vandepitte J, Verbist L, De Maeyer-Cleempoel S. Effect of spiramycin on the nasopharyngeal carriage of Neisseria meningitidis. Chemotherapy 27:325-33, 1981.
38. Kamme C, Kahlmeter G. Evaluation of spiramycin in meningococcal carriage. Scand J Infect Dis 11:229-32, 1979.
39. World Health Organization Department of Communicable Disease Surveillance and Response. Prevention and control of epidemic meningococcal disease in Africa: Report of a WHO Technical Consultation Meeting, Burkina Faso 2002. WHO/CDS/CSR/GAR/2003.10. World Health Organization, Geneva, 2003.